Title:
【発明の名称】平滑筋細胞が関連する疾患を処置するためのT―BAM(CD40L)技術の治療適用
Document Type and Number:
Japanese Patent JP2000515507
Kind Code:
A
Abstract:
Activation of smooth muscle cells bearing CD40 on their cell surface by CD40 ligand is inhibited by contacting the smooth muscle cells with an anti-T-BAM (CD40L) antibody capable of inhibiting the interactions between CD40 ligand and the CD40-bearing smooth muscle cells, in an amount effective to inhibit activation of the smooth muscle cells. Activation of smooth muscle cells bearing CD40 on their surface by CD40 ligand in a subject is inhibited by administering to the subject an anti-T-BAM (CD40L) antibody capable of inhibiting the interaction between CD40 ligand and the smooth muscle cells, in an amount effective to inhibit activation of the cells. Conditions dependent on CD40 ligand-induced activation of CD40-bearing cells smooth muscle cells are treated, in particular inflammatory bowel disease.
Inventors:
Erin, Michael Jay.
Redderman, Seth
Chess, leonard
Carpathus, Mikhail N.
Thomas, David W..
Redderman, Seth
Chess, leonard
Carpathus, Mikhail N.
Thomas, David W..
Application Number:
JP50540498A
Publication Date:
November 21, 2000
Filing Date:
July 03, 1997
Export Citation:
Assignee:
The Trustees of Columbia University in the City of New York
Biogen, Inc.
Biogen, Inc.
International Classes:
A61K38/00; A61K38/17; A61K39/395; A61K45/00; A61P1/00; A61P9/00; A61P9/10; A61P13/10; A61P17/00; C07K14/705; C07K16/28; C12P21/08; C12N15/02; C12R1/91; (IPC1-7): A61K45/00; A61K38/00; A61K39/395; A61P1/00; A61P9/00; A61P9/10; A61P13/10; A61P17/00; C07K16/28; C12N15/02
Attorney, Agent or Firm:
Shusaku Yamamoto